
Jesus Anampa Mesias
Advertisement
Articles by Jesus Anampa Mesias


24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study
BySara A. Hurvitz, MD,Anne F. Schott, MD,Cynthia X. Ma, MD, PhD,Erika P. Hamilton, MD,Rita Nanda, MD,George Zahrah,Natasha Hunter, MD,Antoinette R. Tan,Melinda L. Telli, MD,Jesus Anampa Mesias,Rinath Jeselsohn,Pamela N. Munster, MD,Haolan Lu,Richard Gedrich,Cecile Mather,Janaki Parameswaran,Hyo S Han
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Sunvozertinib Improves PFS vs Chemotherapy in EGFR+ NSCLC
2
The Evolution of Artificial Intelligence in Oncology: Impact on Trials, Workflows, and Outcomes
3
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
4
Selinexor Combo Improves Spleen Volume Reduction in Myelofibrosis
5

